Trial Profile
A PK/PD study of Ixazomib in Japanese mutiple myeloma patients with renal or hepatic impairment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Pharmacokinetics
- 10 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 21 Aug 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Apr 2018 New trial record